Drug Profile

PMC 002R

Alternative Names: Anti-KDR/TIE2 bispecific antibody - PharmAbcine; Anti-VEGFR2/TIE2 bispecific antibody - PharmAbcine; PMC-002R

Latest Information Update: 28 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PharmAbcine
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action TIE-2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in South Korea (IV, Injection)
08 Mar 2019 Preclinical trials in Cancer in South Korea before March 2019 (IV)
08 Mar 2019 PharmAbcine intends to submit an IND application for phase I trial in Cancer in the US

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com